Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Glaxo Wellcome
In this open-label study antiretroviral-experienced patients receive Combivir (3TC/AZT tablet) plus 1592U89 (abacavir) and 141W94 twice daily for 48 weeks.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients must have:
CD4 count greater than 50 cells/mm3.
HIV RNA less than 50,000 copies/ml.
No active AIDS (excluding CD4 count less than 200 cells/mm3).
Ability to comply with dosing schedule and protocol evaluations.
Prior Medication:
Allowed:
AZT or non-nucleoside reverse transcriptase inhibitors (NNRTIs).
You may not be if
Co-existing Condition:
Patients with any of the following symptoms or conditions are excluded:
Active AIDS (not excluding CD4 count less than 200).
Malabsorption syndrome affecting drug absorption.
Serious medical condition that would compromise safety of the patient.
Concurrent Medication:
Excluded:
AZT or NNRTIs.
More than 1 week treatment with any protease inhibitor.
Enrollment in any other investigational drug protocol.
Patients with the following prior conditions are excluded:
History of clinically relevant pancreatitis or hepatitis within the past 6 months.
Required:
Antiretroviral therapy with either single or double reverse transcriptase inhibitors.
Clareo Health | A Study of Combivir Plus Abacavir Plus 141W94 in Patients Who Previously Have Used Anti-HIV Drugs
